Ajan Reginald

Ajan Reginald is an entrepreneur and biotech executive who currently serves as Chief Executive Officer of Cardiogeni PLC. They are Executive Director and Co-Founder of Cell Therapy Limited and Managing Director of Celixir, roles they have held since 2009 and 2016 respectively. They previously led R&D, clinical, and IP teams as Chief Technical Officer at Novacyt Group (2021–2022) and guided NHS deployment of rapid PCR testing as Chief Operating Officer during the COVID-19 pandemic, including scale-up of manufacturing. They earned a BDS in Dental Surgery from the University of London, an MSc in Experimental Therapeutics from the University of Oxford, an MBA in Biotechnology from Kellogg (Northwestern), and an AMP from Harvard Business School, along with a Fulbright scholarship in Business Administration and Management.